FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website www.fitscreening.eu/patients

 

 

Newsstand

Check out the latest news from all EMEA countries.

Sysmex Europe GmbH organises a blood donation and sport event on 3 December Blutspendeaktion bei Sysmex – 70 Blutspende-Helden zum 50. Firmenjubiläum Sysmex Launches their First Subsidiary in Egypt and North Africa Rozvoz zboží v průběhu vánočních svátků a na přelomu roku 2018/2019 Конференция в городе Благовещенске Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers VII Межрегиональная Научно-практическая конференция "Розовая Лента" Congratulations to our CEO Hisashi Ietsugu! Sysmex slaví půl století od založení! Конференция «Совершенствование организации онкологической и гематологической помощи населению в свете майских указов президента В.В. Путина 2018. Инновационные подходы к диагностике и лечению в онкологии» Die neue Ausgabe unseres Kundenmagazins Xtra ist da! Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers Clinical evaluation of Sysmex Inostics’ plasma NGS liquid biopsy technology to complement mammography when screening for early stage breast cancer presented at the 2018 ASCO annual meeting CytoCell und weitere Oxford Gene Technology Produkte bei Sysmex erhältlich
Sysmex XN – TAILORING YOUR HAEMATOLOGY
See the scalability of XN
See the features